Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090241 | 0.94 | CRHR1 (0.31) | TRPA1CRHR1 | |
| SCHEMBL4109936 | 0.94 | TRPA1 (0.37) | TRPA1CRHR1 | |
| SCHEMBL4106287 | 0.91 | SMN1; SMN2 (0.35) | TRPA1CRHR1 | |
| SCHEMBL4090336 | 0.90 | TRPA1 (0.38) | TRPA1CRHR1 | |
| SCHEMBL4090274 | 0.90 | TRPA1 (0.37) | TRPA1CRHR1 | |
| SCHEMBL4102524 | 0.89 | CRHR1 (0.33) | TRPA1CRHR1 | |
| SCHEMBL4097513 | 0.89 | PDE5A (0.35) | TRPA1CRHR1 | |
| SCHEMBL4107196 | 0.88 | RXFP1 (0.38) | TRPA1EPAS1CRHR1 | |
| SCHEMBL4096264 | 0.88 | GPBAR1 (0.33) | TRPA1 | |
| SCHEMBL4103892 | 0.88 | GPBAR1 (0.35) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | claimed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | claimed |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | TRPA1 688/4885EPAS1 1728/4885CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.